Comments
Centrum Broking
Aurobindo Pharma (Buy)
CMP: ₹790.85
Target: ₹1,270
Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
We maintain our ‘Buy’ rating on Aurobindo Pharma (APL) and revise the target price to ₹1,270 (earlier ₹1,010) based on 18x March 2020E EPS of ₹70.4. APL has agreed to acquire the dermatology and oral solid business of Sandoz — a division of Novartis AG, Switzerland and three manufacturing sites in the US for $900 million (₹6,300 crore). This would make APL the second-largest player in dermatology and the second-largest generic player by prescriptions in the US. The deal also includes over 300 products, pending ANDAs, in-licensed products and FTF products, thus making APL a leading player in the US. APL is among our top picks in the pharma sector.
Risks: Key risks to our assumptions include slower growth in the US business and regulatory risks for its manufacturing facilities.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.